TCR2 Therapeutics Inc.
NASDAQ: TCRR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Garry E. Menzel
- Employees
- 58
- Headquarters
- Cambridge, United States
- IPO year
- 2019
- Market cap
- $58.1M
- Website
- https://www.tcr2.com
Loading TCRR…
Loading profile data…Frequently asked questions about TCRR
What does TCR2 Therapeutics Inc. (TCRR) do?
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently bei...
Where does TCRR trade?
TCR2 Therapeutics Inc. (TCRR) trades on the NASDAQ Global Select.
What sector is TCRR in?
TCR2 Therapeutics Inc. (TCRR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TCR2 Therapeutics Inc.?
Garry E. Menzel is the chief executive officer of TCR2 Therapeutics Inc. (TCRR).
Where is TCR2 Therapeutics Inc. headquartered?
TCR2 Therapeutics Inc. is headquartered in United States.
Does TCRR pay a dividend?
TCR2 Therapeutics Inc. (TCRR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TCRR go public?
TCR2 Therapeutics Inc. (TCRR) completed its initial public offering in 2019.